Skip to content

Attending ISPOR, Montreal, May 31- June 4, 2014

by Peter Winters on April 11th, 2014

I am looking forward to attending ISPOR in May/June this year, which is being held in my home town of Montreal. It looks a very interesting agenda, at a very reasonable price, and hopefully a chance to catch-up with some pharma friends.

Here are a list of the events and papers that I am planning to attend:

Saturday, May 31

Monday, June 2

  • FIRST PLENARY SESSION: THE USE OF “BIG DATA” – WHERE ARE WE AND WHAT DOES THE FUTURE HOLD?
  • IP2: DOES HEALTH ECONOMICS HAVE A ROLE IN THE NEW ERA OF PERSONALIZED MEDICINE?
  • PREDICTIVE ANALYTICS:  PROVIDING NOVEL APPROACHES TO ENHANCE OUTCOMES RESEARCH LEVERAGING BIG AND COMPLEX DATA
  • DETERMINING COMPARATIVE EFFECTIVENESS BENCHMARKS FOR EMERGING TREATMENTS FOR HEPATITIS C VIRUS (HCV) INFECTION IN THE SINGLE ARM STUDY DESIGN SETTING
  • THE POTENTIAL IMPACT OF RECOMMENDATIONS MADE THROUGH THE COMMON DRUG REVIEW PROGRAM AT THE CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH

Tuesday, June 3

  • EMERGING ACCESS BARRIERS AND EVIDENCE REQUIREMENTS FOR ONCOLOGY THERAPIES: EXPERIENCES ACROSS THREE COUNTRIES
  • SECOND PLENARY SESSION: WHAT ARE THE ADVANTAGES AND DISADVANTAGES OF USING OBSERVATIONAL DATA AS THE BASIS OF DECISION MAKING IN HEALTH CARE? HOW COULD THIS AFFECT THE FUTURE OF RANDOMIZED CONTROLLED TRIALS?
  • IP9: THE NEXT FRONTIER FOR RISK-SHARING AGREEMENTS IN THE UNITED STATES:  DOES THE CHANGING HEALTH CARE LANDSCAPES BRING NEW PROMISE FOR PARTNERSHIPS BETWEEN MANUFACTURERS AND PAYERS?
  • IP14: VALUE-BASED PRICING ACROSS INDICATIONS: ARE THE CONCEPTUAL AND IMPLEMENTATIONAL CHALLENGES WORTH IT?
  • W19: CHOICE DEFINES VALUE: TURNING PREFERENCES OF MULTIPLE STAKEHOLDERS INTO EVIDENCE FOR HEALTH CARE DECISION MAKING
  • CONJOINT ANALYSIS – STATISTICAL ANALYSES, RESULTS & CONCLUSIONS GOOD RESEARCH PRACTICES TASK FORCE

Wednesday, June 4

  • IP16: PERSONALIZED MEDICINE IN THE ERA OF BIG DATA: HOW WILL THIS AFFECT YOU?
  • THIRD PLENARY SESSION: TO WHAT EXTENT SHOULD VALUE FOR MONEY DERIVED FROM HEALTH ECONOMIC ANALYSIS BE USED IN HEALTH CARE POLICY DECISION MAKING?
  • BRIDGING TO COMPARATIVE EFFECTIVENESS: WHAT REALLY MATTERS?
  • W25: GOOD PRACTICE GUIDELINES FOR QALYs: ISPOR’S DANGEROUS OMISSION?

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

From → Presentations

Comments are closed.